NCT02246686View on ClinicalTrials.gov

Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2016

Conditions
Colitis, Ulcerative
Interventions
DRUG

STW5-II (Iberogast N, BAY98-7410)

Application over 12 weeks 20 drops three time daily

DRUG

Placebo

Application over 12 weeks 20 drops three time daily

Trial Locations (8)

14109

Berlin

20249

Hamburg

21339

Lüneburg

23538

Lübeck

45276

Essen

50937

Cologne

67067

Ludwigshafen am Rhein

85221

Dachau

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02246686 - Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients | Biotech Hunter | Biotech Hunter